Stockscreener 앱 받기
40.61
1.35%
0.54
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 1,339 Shares of Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 2,678 Shares of Stock - MarketBeat
Castle Biosciences Inc (FRA:086) Stock Price, Trades & News - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What drives Castle Biosciences Inc stock priceWeekly Market Snapshot & Affordable Trading Plans - earlytimes.in
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline - MSN
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 830 Shares - MarketBeat
Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus - Yahoo Finance
Is Castle Biosciences Inc. stock vulnerable to regulatory risksHealthcare Stock Analysis & Free Professional Investment Consultations - bollywoodhelpline.com
Breakouts Watch: Why Castle Biosciences Inc. stock is considered a top pick2025 Sector Review & Real-Time Volume Triggers - moha.gov.vn
What makes Castle Biosciences (CSTL) a good fit for 'trend investing' - MSN
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' - sharewise.com
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt? - 富途牛牛
Castle Biosciences stock hits 52-week high at 40.66 USD - Investing.com
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High After Analyst Upgrade - MarketBeat
Castle Biosciences stock hits 52-week high at 40.66 USD By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Receives Analyst Rating Update with Ra - GuruFocus
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at Canaccord Genuity Group - MarketBeat
Is Castle Biosciences Inc. stock a top momentum playWeekly Investment Recap & Safe Swing Trade Setup Alerts - Улправда
Why Castle Biosciences Inc. stock is favored by top institutionsJuly 2025 Chart Watch & Smart Investment Allocation Tips - Улправда
Is Castle Biosciences Inc. stock positioned for digital transformationJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - Улправда
Castle Biosciences (NASDAQ:CSTL) Insider Sells $20,380.36 in Stock - MarketBeat
Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 14,888 Shares - MarketBeat
Why retail investors favor Castle Biosciences Inc. stockPortfolio Value Summary & Fast Momentum Entry Tips - Улправда
Can Castle Biosciences Inc. stock continue upward trend2025 Biggest Moves & Advanced Swing Trade Entry Alerts - DonanımHaber
Castle Biosciences (CSTL) Awards Restricted Stock Units to New E - GuruFocus
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Castle Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule - TradingView — Track All Markets
Can Castle Biosciences Inc. stock maintain operating marginsTrade Entry Report & Fast Exit and Entry Trade Guides - Улправда
Is Castle Biosciences Inc. stock a buy before product launchesMarket Trend Review & Real-Time Volume Analysis - Улправда
Is Castle Biosciences Inc. stock trading at a premium valuationJuly 2025 Price Swings & Long-Term Safe Return Strategies - Улправда
Squarepoint Ops LLC Buys 28,359 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
COO Oelschlager Files To Sell 14,888 Of Castle Biosciences Inc [CSTL] - TradingView — Track All Markets
Castle Biosciences (CSTL) CEO reports stock sales under 10b5-1 plan - Stock Titan
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Reveals Enhanced Predictive Method for Uveal Melanoma Outcomes - GuruFocus
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study - Investing.com
Castle Biosciences Announces Key Study Findings on Uveal Melanoma Risk Stratification Using DecisionDx-UM and PRAME Combination - Quiver Quantitative
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma - GlobeNewswire
CFO Stokes Sells 4,496 ($168.4K) Of Castle Biosciences Inc [CSTL] - TradingView — Track All Markets
Castle Biosciences (CSTL) CCO reports sale of 13,200 shares - Stock Titan
Castle Biosciences (CSTL) CFO reports 4,496-share insider stock sale - Stock Titan
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test - Yahoo Finance
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at BTIG Research - MarketBeat
Castle Biosciences, Inc. $CSTL Shares Bought by Braidwell LP - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
2.56%
2.06%
자본화:
|
볼륨(24시간):